ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

FDA Blocks Nine More INDs; Cooperative Group Chairmen, DeVita Blast “Lack of Expertise”

January 7, 1977

Breast Cancer: Working Group Sets Broad Agenda For Genetic Research

January 10, 1997

ASCO To Open Abstracts To Everyone Prior To Annual Meeting.

November 16, 2007

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

October 31, 2014

High-Priority Radiation Therapy Research Projects Approved By DCT Board of Counselors

March 26, 1976

European Commission Approves Subcutaneous Rituximab

March 28, 2014